Nanosonics (ASX:NAN) carries a consensus analyst rating of Buy. Of the 7 analyst recommendations recorded, 5 are Buy or equivalent, 2 are Hold and 0 are Sell or equivalent. The mean price target is A$3.88, with targets ranging from A$3.20 to A$5.15, against a …
On 31 August 2026, EMVision (ASX:EMV) reported more than 200 patients enrolled across the trial’sTrainingand primary-analysis cohorts. The company also stated that no device-related adverse events had been reported at that point. That observation does not establish diagnostic accuracy or guarantee regulatory approval. Recruitment …
Cochlear Limited (ASX:COH) is the global leader in implantable hearing solutions, according to its official website, with products spanning cochlear and bone-conduction implant systems. The company’s FY26 result shows a year of softer implant revenue and lower margins alongside product adoption, improved cash generation …
CSL Limited (ASX:CSL) is a global biopharma company focused on plasma-derived therapies, vaccines and medicines for serious and complex diseases. Its FY26 result shows a business undergoing a broad reset: underlyingEarningsremained profitable, but restructuring and impairment charges moved the statutory result into loss. The …
Neogen (NASDAQ:NEOG) reported fiscal first-quarter 2027revenueofUSD 222.8 millionon October 6, 2026, up 6.5 percent and 8.1 percent on a core basis, above itsoutlookrange ofUSD 207 milliontoUSD 209 million.
In a release at 5:31 p.m. ET on October 7, 2026, Medtronic (NYSE:MDT) said the final exchange ratio is 4.5939 MiniMed shares for each Medtronic ordinary share accepted. The company indicated that that the calculated ratio would have exceeded the upper limit of 4.5939, …
Ansell Limited is a global provider of personal protection and safety solutions, serving customers across healthcare and industrial markets. In FY26, the company reported higher sales,Earningsand cash flow while navigatingTariffand supply-chain pressures. The result also sets the context for FY27, when management is focusing …
In a release issued at 7:00 a.m. CET on October 8, 2026 (1:00 a.m. ET), argenx said it will discontinue the Phase 3 UNITY study of efgartigimod SC in adults with moderate to severe Sjögren's disease. An independent data monitoring committee recommended stopping after …
Ramsay reported FY26 underlying EBIT of A$1.1622 billion, up 11.5% from A$1.0426 billion in FY25. Underlying NPAT attributable to shareholders increased 19.3% to A$364.1 million.
Sonic reported FY26Revenueof A$10.867 billion, up 12.7% from the prior year.